Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)
NCT02628717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 558
Last updated 2017-09-06
Summary
Since the availability of interferon free direct acting antivirals (DAA) the centers authorized to prescribed these drugs in Austria submitted their data to a central data base (AURIC) using treatment regimes without interferon and ribavirin in patients with advanced liver disease (F3/4)
Conditions
- Chronic Hepatitis C
- Cirrhosis
Sponsors & Collaborators
-
Medical University of Vienna
lead OTHER
Principal Investigators
-
Harald Hofer, MD,Prof · Medical University of Vienna
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-07-31
- Primary Completion
- 2016-12-31
- Completion
- 2017-09-30
Countries
- Austria
Study Locations
More Related Trials
-
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
NCT01591460 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
NCT01667731 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
NCT02405013 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
NCT02607735 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
NCT00793793 ·Status: COMPLETED ·Phase: PHASE1
-
Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.
NCT00383864 ·Status: COMPLETED ·Phase: PHASE4
-
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
NCT01732796 ·Status: COMPLETED ·Phase: PHASE3
-
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
NCT02625909 ·Status: COMPLETED ·Phase: PHASE3
-
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
NCT03855917 ·Status: RECRUITING ·Phase: PHASE4
-
A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
NCT02292706 ·Status: TERMINATED
-
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
NCT02996682 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
NCT01701401 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
NCT01625338 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
NCT01726517 ·Status: COMPLETED ·Phase: PHASE2
-
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
NCT02128217 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
NCT02073656 ·Status: COMPLETED ·Phase: PHASE3
-
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing
NCT02068963 ·Status: COMPLETED
-
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
NCT02738333 ·Status: COMPLETED ·Phase: PHASE3
-
A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
NCT01773070 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
NCT01180790 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
NCT01508130 ·Status: COMPLETED
-
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
NCT02822794 ·Status: COMPLETED ·Phase: PHASE3
-
Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4
NCT00277862 ·Status: COMPLETED ·Phase: PHASE4
-
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
NCT02582658 ·Status: COMPLETED
-
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
NCT01482767 ·Status: COMPLETED ·Phase: PHASE3